Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

Charlotte Steffensen, Merete Lund Mægbæk, Peter Laurberg, Marianne Andersen, Caroline Kistorp, Helene Nørrelund, Jakob Dal, Jens Otto Lunde Jørgensen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind176
Udgave nummer1
Sider (fra-til)58-60
ISSN0041-5782
StatusUdgivet - 6. jan. 2014

Fingeraftryk

Hyperprolactinemia
Prolactinoma
Parkinson Disease
cabergoline

Citer dette

Steffensen, C., Mægbæk, M. L., Laurberg, P., Andersen, M., Kistorp, C., Nørrelund, H., ... Jørgensen, J. O. L. (2014). Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi. Ugeskrift for Laeger, 176(1), 58-60.
Steffensen, Charlotte ; Mægbæk, Merete Lund ; Laurberg, Peter ; Andersen, Marianne ; Kistorp, Caroline ; Nørrelund, Helene ; Dal, Jakob ; Jørgensen, Jens Otto Lunde. / Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi. I: Ugeskrift for Laeger. 2014 ; Bind 176, Nr. 1. s. 58-60.
@article{6b793cc70e70417cb657436535deba75,
title = "Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktin{\ae}mi",
abstract = "Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.",
author = "Charlotte Steffensen and M{\ae}gb{\ae}k, {Merete Lund} and Peter Laurberg and Marianne Andersen and Caroline Kistorp and Helene N{\o}rrelund and Jakob Dal and J{\o}rgensen, {Jens Otto Lunde}",
year = "2014",
month = "1",
day = "6",
language = "Dansk",
volume = "176",
pages = "58--60",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "1",

}

Steffensen, C, Mægbæk, ML, Laurberg, P, Andersen, M, Kistorp, C, Nørrelund, H, Dal, J & Jørgensen, JOL 2014, 'Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi', Ugeskrift for Laeger, bind 176, nr. 1, s. 58-60.

Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi. / Steffensen, Charlotte; Mægbæk, Merete Lund; Laurberg, Peter; Andersen, Marianne; Kistorp, Caroline; Nørrelund, Helene; Dal, Jakob; Jørgensen, Jens Otto Lunde.

I: Ugeskrift for Laeger, Bind 176, Nr. 1, 06.01.2014, s. 58-60.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

AU - Steffensen, Charlotte

AU - Mægbæk, Merete Lund

AU - Laurberg, Peter

AU - Andersen, Marianne

AU - Kistorp, Caroline

AU - Nørrelund, Helene

AU - Dal, Jakob

AU - Jørgensen, Jens Otto Lunde

PY - 2014/1/6

Y1 - 2014/1/6

N2 - Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

AB - Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

M3 - Tidsskriftartikel

VL - 176

SP - 58

EP - 60

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 1

ER -

Steffensen C, Mægbæk ML, Laurberg P, Andersen M, Kistorp C, Nørrelund H et al. Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi. Ugeskrift for Laeger. 2014 jan 6;176(1):58-60.